How is Biotech Venture Funding constructed?
Published by Deepstory Research as the methodology attached to Biotech Venture Funding. Scope and source attribution are bounded by that Evidence Brief.
Procedure and scope
Two series with deliberately different scopes: "global biotech" is the broad sector total, "biopharma" is the narrower drug-developer subset. They are NOT alternative estimates of the same quantity and should not be compared point-to-point. Venture funding totals vary materially between data providers depending on whether crossover rounds, corporate venture and non-dilutive grants are counted. Each series here is kept to a single provider so the trend within a series is consistent. CAVEAT: 2020, 2022 and 2023 global totals are described qualitatively in the cited sources as a "funding winter" but no figure is published, so those years are omitted rather than estimated from the narrative. Re-verified 2026-08-10.
Known failure modes and limits
- Stage or therapeutic-area breakdowns.
- Deal counts or median round sizes.
- Returns or exit outcomes.